Acutaas Chemicals Ltd
Acutaas Chemicals Q3 FY26 Results & Concall Highlights
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.
From Acutaas Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16).
- CDMO business is projected to cross INR 1,000 crores revenue by FY 2028, driven by multiple validated products and new contracts (Page 12, 17).
- Battery chemical segment, especially products like vinyl carbonate (VC) and fluoroethylene carbonate (FEC), is in early stages with capacity and contracts in place; further products are planned for commercialization in mid-FY 2027 onwards (Page 8, 16).
- Semiconductor chemical verticals (including Baba Fine Chem and Indichem JV) are expected to contribute meaningfully by 2028 with high EBITDA margins (Page 13, 16).
- Quality growth focus in pharma intermediates, with exiting low-margin products, contributing to steady high single-digit growth (Page 12).
- Overall, strong visibility on contracts and pipeline products support aggressive scaling up of all business verticals through FY 2027 and beyond (Page 17).
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.
- Indichem joint venture (South Korea) investment: INR 130 crores invested so far out of total INR 200 crores announced; capex progressing as per plan; additional investment possible this quarter.
- Battery chemicals segment: No specific capacity announced for two new products; second phase capex part of the INR 220 crore plan.
- Ankleshwar plant utilization currently at 40%; growth till FY '28 expected with possible incremental pharma intermediate capex after 1.5 years based on market conditions.
- Indichem JV capex started 4 months ago, expected completion by calendar end.
- The company has sufficient cash and strong cash flows to fund these investments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has good visibility of contracts for FY '27 and beyond, expecting fast scaling of its business.
- For the additives business, there are fixed pricing contracts in place with variability linked to raw materials and currency.
- The anticancer CDMO segment has long-term supply contracts, with projections extending through FY '28.
- Four new CDMO products validated in the current financial year are expected to start contributing from FY '27.
- Sampling and validation for additional CDMO products are underway, reinforcing a strong pipeline.
- Battery chemical orders for VC and FEC products are already in hand with good revenue visibility for FY '27.
- Two additional battery chemical products are expected to contribute to revenues starting mid-FY '27.
- Indichem joint venture's plant capex is to be completed by calendar year 2026, with revenue expected from next year.
- Overall, the company aims to achieve INR 1,000 crores from CDMO business by FY '28, encompassing multiple projects.
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹433 Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma Ltd (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q3 FY26 results?
Acutaas Chemicals expects to grow revenue by more than 25% year-on-year for the next 3 to 5 years, maintaining strong double-digit growth (Page 16). Acutaas Chemicals aims for sustainable revenue growth above 25% annually for the next 3 to 5 years.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
Total capex for FY '26 is expected around INR 220 crores, slightly lower than earlier guidance of INR 250 crores due to spillover of the second phase of battery chemical and pilot plant capex.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.